Logo

Bruker Shares Continue to Climb After CEO Laukien Buys $1.1M Worth of Stock

May 18, 2005

NEW YORk, May 18 (GenomeWeb News) - Bruker Biosciences CEO Frank Laukien bought more than $1.1 million worth of his company's shares since May 10, sending the stock up 12.7 percent to $3.99 in mid-afternoon trading today.

 

According to Insidercow.com, which tracks insider trading at public companies, Laukien bought 277,430 shares of Bruker stock at prices between $3.60 and $3.00 per share between May 10 and May 17.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.